Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma

British Journal of Cancer

Volumn 88, Issue 9, 2003, Pages 1346-1351

  Verra, N ^a   Jansen, R ^b,c   Groenewegen, G ^b,c   Mallo, H ^a   Kersten, M J ^a   Bex, A ^a   Vyth Dreese, F A ^a   Sein, J ^a   Van De Kasteele, W ^a   Nooijens, W J ^a   De Waal, M ^a   Horenblas, S ^a   De Gast, G C ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Immunotherapy; Multicentre phase II study; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 2; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ALLERGIC REACTION; ANGIONEUROTIC EDEMA; ANOREXIA; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; EOSINOPHIL; EOSINOPHILIA; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; LEUKOCYTOSIS; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MONOCYTE; NATURAL KILLER CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; FEMALE; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; IMMUNOTHERAPY; INTERFERON ALFA-2B; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0037809210     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600915     Document Type: Article

References (26)

1. Bukowski RM (1997) Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80: 1198-1220
2. Bukowski RM (1999) Immunotherapy in renal cell carcinoma. Oncology (Huntingt) 13: 801-810
3. Bukowski RM (2000) Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. Sernin Oncol 27: 204-212
4. de Gast GC, Klumpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH (2000) Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin Cancer Res 6: 1267-1272
5. Favrot MC, Combaret V, Negrier S, Philip I, Thiesse P, Freydel C, Bijmann JT, Franks CR, Mercatello A, Philip T (1990) Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma. J Biol Response Mod 9: 167-177
6. Figlin RA, deKernion JB, Mukamel E, Palleroni AV, Itri LM, Sarna GP (1988) Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation. J Clin Oncol 6: 1604-1610
7. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, CatonJr JR, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345: 1655-1659
8. Fossa SD (2000) Interferon in metastatic renal cell carcinoma. Semin Oncol 27: 187-193
9. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13: 688-696
10. Knop J (1990) Immunologic effects of interferon. J Invest Dermatol 95: 72S-74S
11. Kolitz JE, Welte K, Wong GY, Holloway K, Merluzzi VJ, Engert A, Bradley EC, Konrad M, Polivka A, Gabrilove JL (1987) Expansion of activated T-lymphocytes in patients treated with recombinant interleukin 2. J Biol Response Mod 6: 412-429
12. Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J, Cebon J (1998) Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 161: 1947-1953
13. Mani S, Todd MB, Katz K, Poo WJ (1995) Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 154: 35-40
14. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358: 966-970
15. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM (2000) Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 18: 1928-1935
16. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 338: 1272-1278
17. Negrier S, Maral J, Drevon M, Vinke J, Escudier B, Philip T (2000) Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Cancer J Sci Am 6 (Suppl 1): S93-S98
18. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA (2001) Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19: 3477-3482
19. Ragnhammar P (1996) Anti-tumoral effect of GM-CSF with or without cytokines and monoclonal antibodies in solid tumors. Med Oncol 13: 167-176
20. Sarna G, Figlin R, de Kernion J (1987) Interferon in renal cell carcinoma. The UCLA experience. Cancer 59: 610-612
21. Schiller JH, Hank JA, Khorsand M, Storer B, Borchert A, Huseby-Moore K, Burns D, Wesly O, Albertini MR, Wilding G, Sondel PM (1996) Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study. Clin Cancer Res 2: 319-330
22. Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Levitt D, Fefer A (1988) Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol 6: 669-678
23. Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN (1998) Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res 4: 585-593
24. Vogelzang NJ, Lipton A, Figlin RA (1993) Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol 11: 1809-1816
25. Westermann J, Reich G, Kopp J, Haus U, Dorken B, Pezzutto A (2001) Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study. Cancer Immunol Immunother 49: 613-620
26. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin RA, Belldegrun AS (2002) Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20: 4559-4566